S. 148 · 118th Congress

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act

Stage
Reported from committee
Sponsor
Amy Klobuchar
Introduced
2023-01-30
Latest action
2023-03-01 · Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.

Subjects

Health
Civil actions and liability
Licensing and registrations
Department of Health and Human Services
Prescription drugs
Competition and antitrust
Public participation and lobbying
Business ethics
Drug safety, medical device, and laboratory regulation
Food and Drug Administration (FDA)
Administrative remedies